Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells
transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and
total body irradiation). Peripheral blood is the donor graft source. This study is designed
to estimate disease-free survival (DFS) at 18 months post-transplant.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute